0001662579-23-000097.txt : 20230919
0001662579-23-000097.hdr.sgml : 20230919
20230919192119
ACCESSION NUMBER: 0001662579-23-000097
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230918
FILED AS OF DATE: 20230919
DATE AS OF CHANGE: 20230919
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Adams Kendra
CENTRAL INDEX KEY: 0001991929
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39567
FILM NUMBER: 231265062
MAIL ADDRESS:
STREET 1: C4 THERAPEUTICS, INC.
STREET 2: 490 ARSENAL WAY, SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: C4 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662579
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 475617627
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 490 ARSENAL WAY
STREET 2: SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: (617) 231-0700
MAIL ADDRESS:
STREET 1: 490 ARSENAL WAY
STREET 2: SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
wk-form4_1695165671.xml
FORM 4
X0508
4
2023-09-18
0
0001662579
C4 Therapeutics, Inc.
CCCC
0001991929
Adams Kendra
C/O C4 THERAPEUTICS, INC.
490 ARSENAL WAY #120
WATERTOWN
MA
02472
0
1
0
0
Chief Financial Officer
0
Common Stock
2023-09-18
4
A
0
25000
0
A
46640
D
Stock Option (Right to Buy)
2.15
2023-09-18
4
A
0
111000
0
A
2033-09-17
Common Stock
111000
111000
D
Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on September 18, 2024, subject to the Reporting Person's continued service on each vesting date.
25% of this option shall vest and become exercisable on September 18, 2024, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each vesting date.
/s/ Jolie M. Siegel, Attorney-in-Fact
2023-09-19